The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
PhRMA, a leading drug industry trade group, and the US Chamber of Commerce have also filed suits. More on Medicare drug pricing: Medicare lists first ten drugs selected for pricing negotiations ...
The nation’s leading lobbying group for seniors filed an amicus brief on Monday in Washington, D.C., urging a federal court ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
AstraZeneca joins Johnson & Johnson (), Merck (), and Bristol-Myers in a lawsuit against the U.S. Department of Health and Human Services (HHS) over certain provisions on prices found in President ...
Getting spending on Social Security, Medicare, and Medicaid “under control” is at the top of all the budgeteers’ agenda. While the intention sounds reasonable, spending on these programs is ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
